Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients-Reference-Cited by-同舟云学术

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Zhang Tian¹,Pabla Sarabjot²,Lenzo Felicia L.²,Conroy Jeffrey M.²³,Nesline Mary K.²,Glenn Sean T.²³,Papanicolau-Sengos Antonios²,Burgher Blake²,Giamo Vincent²,Andreas Jonathan²,Wang Yirong²,Bshara Wiam²,Madden Katherine G.⁴,Shirai Keisuke⁴,Dragnev Konstantin⁴,Tafe Laura J.⁴,Gupta Rajan¹,Zhu Jason¹,Labriola Matthew¹,McCall Shannon¹,George Daniel J.¹,Ghatalia Pooja⁵,Dayyani Farshid⁶,Edwards Robert⁶,Park Michelle S⁶,Singh Rajbir⁷,Jacob Robin⁷,George Saby³,Xu Bo³,Zibelman Matthew⁵,Kurzrock Razelle⁸^ORCID,Morrison Carl²³

Affiliation:

1. Department of Medicine, Duke University, Durham, NC, USA

2. R&D, OmniSeq, Inc, Buffalo, NY, USA

3. Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

4. Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

5. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, US

6. Department of Medicine, University of California, Irvine, CA, USA

7. Department of Medicine, Meharry Medical College, Nashville, TN, US

8. Center for Personalized Cancer Therapy, Moores Cancer Center, La Jolla, CA, USA

Funder

OmniSeq, Inc.

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1773200

Reference45 articles.

1. FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

2. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

3. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

4. U.S. Food and Drug Administration. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. FDA.gov. 2018 [accessed 2019 Sep 1]. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm.

5. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of immune checkpoint inhibitors in the treatment of kidney cancer oral metastasis. A case report;Journal of Stomatology, Oral and Maxillofacial Surgery;2024-05

2. Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer;Journal of Personalized Medicine;2024-04-30

3. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer;Journal of Translational Medicine;2024-02-07

4. Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment;Journal of Proteins and Proteomics;2022-12-02

5. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma;Journal for ImmunoTherapy of Cancer;2022-10